The coronavirus vaccine developed by teams at the University of Oxford has been shown to trigger a robust immune response in healthy adults aged 56-69 and those over 70 years of age.

The findings published in -Lancet- on Thursday based on 560 healthy adult volunteers shows that the ChAdOx1 nCoV-19 vaccine is "safe and well tolerated" with a lower reactogenicity profile in older adults than in younger adults, meaning the older age groups could build immunity to the disease.